Caracciolo Matteo, Castello Angelo, Castellani Massimo, Bartolomei Mirco, Lopci Egesta
Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20089 Milan, Italy.
Biomedicines. 2024 Oct 16;12(10):2355. doi: 10.3390/biomedicines12102355.
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has gained a primary role in prostate cancer (PCa) imaging, overcoming conventional imaging and prostate-specific antigen (PSA) serum levels, and has recently emerged as a promising technique for monitoring therapy response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with novel hormonal therapy, taxanes, and radioligand therapy (RLT). In this review, we aim to provide an overview of the most relevant aspects under study and future prospects related to the prognostic role of PSMA PET/CT in mCRPC.
A systematic literature search was performed in the following databases: MEDLINE, PubMed, and EMBASE databases. The study focused exclusively on English-language studies, excluding papers not pertinent to the topic.
PSMA PET imaging offers a higher sensitivity and specificity than conventional imaging and provides accurate staging and efficient diagnosis of distant metastases. The data presented herein highlight the usefulness of PET in risk stratification, with a prognostic potential that can have a significant impact on clinical practice. Several prospective trials are ongoing and will shortly provide more evidence supporting the prognostic potential of PET PSMA data in this clinical scenario.
Current evidence proves the prognostic role of PSMA PET/CT in different settings, with raising relevance also in the context of mCRPC.
前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）在前列腺癌（PCa）成像中发挥了主要作用，克服了传统成像和前列腺特异性抗原（PSA）血清水平的局限性，并且最近已成为一种有前景的技术，用于监测接受新型激素疗法、紫杉烷类药物和放射性配体疗法（RLT）治疗的转移性去势抵抗性前列腺癌（mCRPC）患者的治疗反应。在本综述中，我们旨在概述与PSMA PET/CT在mCRPC中的预后作用相关的最相关研究方面和未来前景。
在以下数据库中进行了系统的文献检索：MEDLINE、PubMed和EMBASE数据库。该研究仅关注英文研究，排除与该主题无关的论文。
PSMA PET成像比传统成像具有更高的敏感性和特异性，并能提供准确的分期和对远处转移的有效诊断。本文提供的数据突出了PET在风险分层中的有用性，其预后潜力可能对临床实践产生重大影响。几项前瞻性试验正在进行中，不久将提供更多证据支持PET PSMA数据在这种临床情况下的预后潜力。
目前的证据证明了PSMA PET/CT在不同情况下的预后作用，在mCRPC背景下的相关性也在增加。
